Details for Patent: 11,969,403

« Back to Dashboard

Which drugs does patent 11,969,403 protect, and when does it expire?

Patent 11,969,403 protects IHEEZO and is included in one NDA.

This patent has twenty-three patent family members in twenty-two countries.

Summary for Patent: 11,969,403

Title:	Topical formulations of chloroprocaine and methods of using same
Abstract:	Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.
Inventor(s):	Augusto Mitidieri, Elisabetta Donati, Clara Bianchi
Assignee:	Sintetica SA , Pilot Corp
Application Number:	US17/008,913
Patent Claim Types: see list of patent claims	Formulation; Compound;

Drugs Protected by US Patent 11,969,403

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harrow Eye	IHEEZO	chloroprocaine hydrochloride	GEL;OPHTHALMIC	216227-001	Sep 27, 2022		RX	Yes	Yes	11,969,403		Y

International Family Members for US Patent 11,969,403

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018332212
Brazil	112020003095
Canada	3070336
Chile	2020000665
China	111163756
Colombia	2020002985